Senores Pharma shares jump over 7% as company acquires 14 ANDAs from Dr. Reddy’s

Senores Pharma shares jump over 7% in trade on March 4.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Senores Pharma share price jumped over 7 percent in trade on March 4 after the company announced the acquisition of 14 Abbreviated New Drug Applications (ANDAs) from Dr.
Reddy’s Laboratories.

Shares of Senores Pharmaceuticals Ltd jumped 7.25 percent to an intraday high of Rs 569 per share on the NSE.

"The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA," the company said in an exchange filing.

Commenting on the acquisition, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said "We are glad to announce the acquisition of a basket of products from Dr Reddy's. It spans across various therapeutic areas with growing consumption. The portfolio consists of controlled substances and general category of products."

"These products can be distributed through multiple/diverse channels, with large requirements in government, retail and specialty clinics. This Portfolio of products significantly increases our products offering in the US, and also it has a significant value in other Regulated and Semi-Regulated markets of the world," it added.

The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by Senores Pharma. This is in line with the Objects of the IPO stated in the Red Herring Prospectus, the company stated in a statement.

The stock price bucked the trend as the shares of pharma companies tumbled as US President Donald Trump's tariffs on Canada and Mexico came into effect, which made investors move away from export-sensitive stocks.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.